December 1, 2010
Arrowhead’s New Report Assesses the State of Global Pain Therapeutics Market
Pain continues to present numerous challenges to the biopharmaceutical industry. According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain. Indeed, pain affects more Americans than cancer, diabetes and cardiac disease combined. Current analgesics only provide modest relief, frequently carry black box safety warnings and are susceptible to abuse.
According to Arrowhead Publishers’ new report entitled The Global Pain Therapeutics Market: Market Trends and R&D Insights, the anticipated arrival of novel analgesics is set to transform this market. GW Pharmaceuticals’ Sativex (GW-1000), Allergan’s Botox (botulinium toxin), Merck’s Telecagepant (MK-0974), Novartis’ Canakinumab (ACZ885) and FoldRX Pharma’s Tafamidis (meglumine) will modernize pain management strategies. The market will enter a highly competitive, transitional era following the COX-2 saga. Investors must differentiate their products to gain blockbuster sales witnessed by Pfizer’s Lyrica (pregabalin) and Celebrex (celecoxib).
With numerous unmet needs, improved diagnosis of painful conditions, the advent of pharmacogenomics driving R&D and 10% of the global population regularly taking analgesia; the pain therapeutics market offers numerous lucrative commercial opportunities.
The Global Pain Therapeutics Market: Market Trends and R&D Insights …
- Analyzes seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and pipeline analysis of each condition to maximize your product’s commercial success
- Identifies the major challenges within pain R&D trends; exploring unmet needs, pain clinical trials, pharmacogenomics, animal pain models and functional imaging techniques
- Analyzes both the clinical and commercial sides of the pain therapeutics market; including key late stage and Phase III/ II candidates and novel drug classes to watch
Although the analgesia market is highly competitive and heavily genericized, growth is expected. Improved diagnosis of fibromyalgia and neuropathic pain will be key driving factors. Sales of pain therapeutics could reach a massive $59 billion by 2015 in the seven major markets.
Biomarkers will transform pain R&D away from the traditional linear, over-simplified model approach. Novel analgesia drug targets will be realized, streamlining clinical trials and optimizing candidate’s efficacy and safety profiles.
Opioids will continue to form the backbone of pain relief due to improved physician prescribing confidence. By 2015, sales of opioids could reach $17 billion, with OxyContin (oxycodone; Purdue) remaining the top-selling branded analgesic until its patent expiration in 2013.